Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Coherus Oncology, Inc.
Rutgers, The State University of New Jersey
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Lepu Biopharma Co., Ltd.
Bristol-Myers Squibb
Seagen Inc.
St. Jude Children's Research Hospital
Centre Hospitalier Universitaire de Besancon
Incyte Corporation
Seagen Inc.
Revolution Medicines, Inc.
Delcath Systems Inc.
Janssen Research & Development, LLC
Pfizer
Peking University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Federation Francophone de Cancerologie Digestive
AstraZeneca
Genentech, Inc.
BioNTech SE
Qilu Pharmaceutical Co., Ltd.
Sun Yat-sen University
M.D. Anderson Cancer Center
Akeso
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Hoffmann-La Roche
Summit Therapeutics
MedImmune LLC
Eastern Cooperative Oncology Group
Neonc Technologies, Inc.
Amgen
Northwell Health
M.D. Anderson Cancer Center
Pfizer
Mayo Clinic
Abramson Cancer Center at Penn Medicine
AstraZeneca
AstraZeneca
MedImmune LLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Genentech, Inc.
Incyte Corporation